

## TOPICAL INDEX – STATE RELEASES 1 - 161

TOPIC	RELEASE #
340-B Program	161
1A Drug Listing	11
Active Pharmaceutical Ingredient & Excipients (Removal)	155, 158
Additional Copies of Releases to SMDs	40
Adjustment Code for Forms CMS-304 & CMS-304a	57, 145
Affordable Care Act (ACA)	155, 157
Allscrips Pharmaceuticals, Inc.	65, 68, 69
AMP Recalculations	107, 109, 110, 112, 140, 148, 149, 150
AMP to states	142
Monthly AMP Methodology (Manufacturer Assumptions)	146
Bankruptcy - Drug Labelers	19, 61, 68, 151, 154, 155, 159
Best Price	
Effect of Sales to HMOs, etc.	137
To DSH Covered Entities	36
Under MPDIMA of 2003	128
Betaseron - Coverage & Reimbursement	38, 40
Bulk Transfer/Buy-Out of Major Pharm. Assets	54, 55
Calphron	76, 79
Caverject Coverage	55
Closure During Federal Furloughs	57
Clotting Factor Drugs	157
Compendia	70, 141
Confidential Information Release	17
Constant Disputes by Drug Labelers	23
Contact Information	65, 92
CPI-U Information	09, 102, 147
Database Backup Files	140
Dataset Name Changes on Quarterly Rebate Tapes	41
Deficit Reduction Act of 2005 (DRA)	144
Deleted Products-No Termination Date	139
Depot Prices-TRRx	137
DESI Code Change	137, 140, 142, 144, 145, 146, 148, 149, 150, 151, 158, 161
Device Deletions	159
Dipyridamole Issue	26
Dispute Resolution:	
Definition	19
E-Mail Address/Contacts	128, 155
Issues	55, 65, 71, 86, 108
Meetings	138, 140, 143, 145, 147
Process Stages	45
State Invoicing	152
Transfer of Function	121
Web Site	122
Workgroup Survey Results	42
Dispute Resolution Meetings	59, 151
Drug Category Change	61, 76
Drug Efficacy Study & Implementation (DESI):	

**TOPICAL INDEX – STATE RELEASES 1 - 161**

<b>TOPIC</b>	<b>RELEASE #</b>
Change Effective Date	20
Change Schedule	18
Effective Date Revisions	23, 24
(State Role In) DESI Process	148
DRUGDEX, a new compendium	70
Drug Emporium, Inc. Effective Date	65
Duplicate Discount/Rebate Mechanism Implementation	33
Effective Date(s) of Rebate Agreements	97
Electronic File Transfer (EFT)	160
E-mail Address (Operations)	140
Enteral Nutritional Products - Coverage	30
Enteral Products	19
Eon Labs Product	117
ESRD Bundled Services	161
Exclusively Pediatric Drugs	157
Experimental Drugs - Coverage	43
Failure of Manufacturers to Notify States of	
Disputes or Pay Rebates	63
FDA/MDRI Data Match	107, 115
FDA Federal Register Notices	148, 149
FDA Voluntary Market Withdrawals	
Darvon/Darvocet	157
Meredia	157
Generic Substitution Laws	67
Goldline OTC Vitamin	102
Haldol Rebates	73, 75, 148
Heparin/Saline Flush Syringes & Other Non-Drug Products	132, 134, 136
Herceptin: Genentech New Product	85
HIPAA – Prescription Numbers	124
Hotline	53
HRSA Notice Published/Exclusion File	98, 101, 106
HRSA – NPI	144
Improper Rebate Withholding/Interest Implications	114
Index for Drug Rebate Notes	31
Information Sharing	57
Interest Calculation under Section V(b)	29, 88, 98
Interest:	
Failure to Pay	65
When PPAs are Submitted	121
Internet:	
Home Page/New Webpage Address	61, 85, 105, 117, 140
Prescription Reimbursement Information	123
Pharmacy Plus Demonstrations	123
Invoices:	
CMS R-144 (State Invoice) – Changes	143, 145, 146, 147, 149, 160
Correct Labeler Address	36
Format	03
Incomplete Drug Labeler Data	18
Incorrect Invoicing	26

**TOPICAL INDEX – STATE RELEASES 1 - 161**

<b>TOPIC</b>	<b>RELEASE #</b>
Remittance Advice Report Survey	35
Submission	19
Submitting for Multiple Quarters	36
Submitting to Drug Labelers	28
Labeler Contact File Changes	26, 32, 128, 132, 152
Lovenox Prefilled Syringes	91
LTE/IRS Drugs	26
Magnetic Media	
New Address for Shipping (Effective 6/1/95)	52
Rejections	15
Shipments	15, 23
Specification Revisions	14, 72, 73
Manufacturer Information Record Specification	20
Manufacturer Name & Address Contact Info Diskette	27
MDR Technical E-mail Address	124, 137
Medicaid Drug Rebate Data Guide for States	146
Medical Supplies & Devices	03, 16, 26
Metric Conversion/Rounding	18
MMA of 2003	128, 130
Monthly AMP Units & File Record Layout	156
Multiple Package Size-Pricing Inconsistency	123
New Drug Determinations—Deletions from MDR	149, 150, 151, 157, 158, 159
New Drug Products	41
New Rebate Agreement Status	23
New Rebate File Formats	157
Non-Drug Products Coverage	132, 134
(Non-Drug) Product Deletions	138, 139, 140, 142, 143, 144, 145, 146, 148, 149, 150, 151, 159
Novartis Rounding All URAs Back to 1991	117
OBRA '93	40
OIG Reports/Reviews	120, 140
Ortho Evra Replacement Patch	134
Overpayments Due to AMP Recalculations	57, 107
Personnel:	
Changes	53, 124, 130, 139, 142
Relocation	52, 83
PHS Drug Pricing Program	44
Physician Administered Drugs	151
Point-of-Sale System (POS) in Pharmacies	85
Policy E-Mail Address	113, 117
Prenatal Vitamins	159
Prior Authorization	55
Prior Period Adjustments	14, 16, 60, 87
Prior Period Adjustments - Eli Lilly & Company	37
Prior Quarter Adjustment Statement (PQAS) Approval	60
Proposed Discount Equal Access Legislation	51
Publication of Drug Rebate Regulations CMS-2175-FC	126
Publication of Drug Rebate Regulations MB-46-P	55

**TOPICAL INDEX – STATE RELEASES 1 - 161**

<b>TOPIC</b>	<b>RELEASE #</b>
Quarterly Prices, Late Submission	33
Quarterly Rebate Offset Amount (QROA)	157
Quarterly Reporting - Form CMS-64.r	40
Quarterly Tape Submission to CMS	60, 72, 130
Quarterly Update File	14
Questions and Answers	65
Re-activated NDCs	145
Rebate Agreements:	
Start Date Procedures	102
Separate/Supplemental	102
Rebate/Reimbursement Issues	64, 113
Rebates:	
Calculation Formula	07
Drugs Purchased Through the FSS	113
Less than Administrative Costs	40
Nonpayment	94
Partial Payments	55
Remittance/Check Address	30
Reconciliation of State Invoice (ROSI) Approval	60
Recordkeeping Regulations	129
Regulation (CMS-2175-F)	136
Regulation (CMS-2238-FC)	
Preliminary Injunction	148
Rejection of State Records Matching LTE Drugs	41
Remittance Advice Report/Workgroup	48, 52, 53, 56
Rescission of Termination for Novopharm USA	39
S-TAG (Systems Technical Advisory Group)	85
Separate Rebate Agreements with Manufacturers	38, 113
Special Advisory Group	16
Special Study – Anti-Load Viral/AIDS Drugs	102
Standard Summary Record Format	13
State Application of the FUL Program	48
State Contact Information	23, 26, 41, 98
State Coverage:	
LTE & IRS Drugs	40
Unit-Dose Drugs	19
State Data Validation Edits	33
State Hearing Process	44
State Invoice/Utilization Data File Format	158
State Invoices Containing Universal Product Codes	51
State Notification Method Change	148
State Pharmacy Assistance Programs	
Exemption From Medicaid Best Price	140
Revised Criteria	124
State Plan Amendment Requirement	47
State Quarterly URA Tape	
Labeler Contact Information	134
Mailing	133
Updated File Format	157

**TOPICAL INDEX – STATE RELEASES 1 - 161**

<b>TOPIC</b>	<b>RELEASE #</b>
State Responsibility - Terminated Drugs	19
State Utilization Data Study (SUDS)	33
T-bill Rates	83, 86, 132, 149, 150, 151
Technical Contact E-mail Address	140
Termination Date (NDC)	79
Terminated/Deleted Records	44
Market Withdrawals	159
Termination From Program	55
Therapeutic Equivalency Code	64
Timely Receipt of Tapes/Notices of Mailing	45
Tolerance Threshold Clarification	
For Interest	48
Rebate Amount Adjustments	44
Training Guide Obsolete	145
TRICARE Retail Pharmacy Benefit Plan	152
Unapproved Drugs—Deletions from DDR	151
Unit-Dose Packaging	15
Unit Per Package Size	03
Change for Boehringer Ingelheim Product	123
Unit Rebate Amount (URA):	
Additional Amounts in 3/1998 File	85
Edits	43
Erroneous Amounts	51
First-Time Reporting on State Tape	132
Incorrect Amounts for 1Q98	79, 80
Invoice when the Amount is Zero	44
New Rounding Method	98, 100, 101, 106
Recalculations	111
Unit Rebate Offset Amount (UROA)	157
Unit Type:	
Changes and Prior Period Adjustments	43
Conversion Date Changed	34
Reporting	156
Revisions	32, 83
Units Per Package Size	156
UPPS Less Than 1.0	19
UPPS Used for Calculating Utilization	61
Use of Information from Outside Sources	48
Utilization Adjustments for Prior Calendar Quarters	67, 72
Receipt	29, 31
Utilization Data:	
Annual Branded Prescription Drug Fee (9008)	159
Changes to Labelers	57
Corrections/Problems	18, 51, 72
Late Submission	18
MCO/FFS Units	160
Record Format	08, 13, 72, 147, 149, 160
Set Naming Requirements	19
Tapes/Confirmation Letter	19, 30, 40, 45, 58, 72, 82

## TOPICAL INDEX – STATE RELEASES 1 - 161

<b>TOPIC</b>	<b>RELEASE #</b>
Transmission of Discrepancy Reports	160
Transmitting Corrections/Adjustments to CMS	16, 40, 72
Utilization Discrepancy Report	139
Utilization Tape Record Specification	67, 72, 73, 98, 105
Vaccine:	
Deletions	26, 157
Exclusions	19, 23
Policy Clarification	25
Viagra Coverage	81
Vitasert	64
Warrick Pharmaceuticals (Sodium Chloride Solution)	98
Xenical Coverage	97
Y2K	72, 87